{
  "id": "5962ca310b04490e",
  "title": "Ultragenyx Completes Rolling Submission of Biologics License Application ( BLA ) to U . S . FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia ( GSDIa ) ",
  "description": "20251230T224500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/31/tmt-newswire/globenewswire/ultragenyx-completes-rolling-submission-of-biologics-license-application-bla-to-us-fda-for-dtx401-aav-gene-therapy-for-glycogen-storage-disease-type-ia-gsdia/2251198",
  "published_at": "20251230T224500Z",
  "fetched_at": "2025-12-31T00:23:34.453563+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "gene therapy",
    "fda"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/31/tmt-newswire/globenewswire/ultragenyx-completes-rolling-submission-of-biologics-license-application-bla-to-us-fda-for-dtx401-aav-gene-therapy-for-glycogen-storage-disease-type-ia-gsdia/2251198",
    "url_mobile": "https://www.manilatimes.net/2025/12/31/tmt-newswire/globenewswire/ultragenyx-completes-rolling-submission-of-biologics-license-application-bla-to-us-fda-for-dtx401-aav-gene-therapy-for-glycogen-storage-disease-type-ia-gsdia/2251198/amp",
    "title": "Ultragenyx Completes Rolling Submission of Biologics License Application ( BLA ) to U . S . FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia ( GSDIa ) ",
    "seendate": "20251230T224500Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/31/883868.png",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}